Recombinant human endostatin

Drug Profile

Recombinant human endostatin

Alternative Names: Endostatin

Latest Information Update: 04 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Childrens Hospital Boston
  • Developer Alchemgen Therapeutics; Childrens Hospital Boston
  • Class Angiostatic proteins; Antineoplastics; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Neuroendocrine tumours

Highest Development Phases

  • Discontinued Adenocarcinoma; Atherosclerosis; Cancer; Malignant melanoma; Neuroendocrine tumours

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 17 Oct 2007 Preclinical trials in Cancer in Asia (SC)
  • 10 Feb 2004 EntreMed transfers all rights to endostatin to Children's Medical Center Corporation and Alchemgen Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top